A Review of the Efficacy of Popular Eye Cream Ingredients
Rajaa Shoukfeh BS, Hanin Hamie BS, Reem Yassine BS, Dilara Turk MD, Farhan Huq MD, Meena Moossavi MD, MPH 
The real-world impact of a hand-held, at-home narrow-band UVB phototherapy system with proactive monitoring and coaching for mild-to-severe psoriasis: a retrospective, multicenter, observational study
Justine G. Schneider BS, Teddy Fulham, Recep Emre Hacisoftaoglu, Stacy Roberts, Jennifer Bishop, Ronald L. Moy MD
Dermatology TikTok™ videos: applicable considerations
Karen Vo, OMS-2, Navid Ezra, MD
Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy
Sang Hee Park, Yichen Zhong, Adam Sima, Vardhaman Patel, Joe Zhuo, Carla Roberts-Toler, Brandon Becker, Sara Hovland, Bruce Strober
Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
Neil J. Korman, Thierry Passeron, Kenneth B. Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B. Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli,
Renata M. Kisa, Subhashis Banerjee, Diamant Thaçi
A Case Series of Live Attenuated Vaccine Administration in Dupilumab-Treated Children With Atopic Dermatitis
Elaine C. Siegfried, Charlton Camp, Lara Wine Lee, Jonathan M. Spergel, Sumeet Uppal, Anna Coleman, Brad Shumel, Randy Prescilla, Ashish Bansal, Sonya L. Cyr
Efficacy of Dupilumab in Infants and Preschoolers With Atopic Dermatitis up to 1 Year
Amy S. Paller, Jason Jernigan, Elaine C. Siegfried, Jing Xiao, Randy Prescilla, Ashish Bansal
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 2-year efficacy by prior biologic treatment in the phase 3 POETYK PSO program
Richard B. Warren, April W. Armstrong, Shinichi Imafuku, Carle Paul, Leon Kircik, Elizabeth Colston, Thomas Scharnitz, Tao Wang, Subhashis Banerjee,
Bruce Strober
Is there a clinically relevant risk of hyperkalemia with topical clascoterone treatment?
James Del Rosso, Linda Stein Gold, Nicholas Squittieri, Diane Thiboutot
Long-term safety and efficacy of 1% clascoterone cream in patients ≥12 years old with acne vulgaris
L.awrence F Eichenfield, Adelaide A Hebert, Linda Stein Gold, Martina Cartwright, Luigi Moro, Jenny Han, Nicholas Squittieri, Alessandro Mazzetti
Patients’ quality of life and satisfaction with treatment in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis
Jayme Heim, J Gabriel Vasquez, Ranga Gogineni, Brad Schenkel, Neal Bhatia
The efficacy and safety of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light for the treatment of facial cutaneous squamous cell carcinoma in situ
Mark S Nestor, Haowei Han, Faraz Yousefian, Ciaran Smythe
Patient-reported symptom relief in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis
J Gabriel Vasquez, Neal Bhatia, Brad Schenkel, Ranga Gogineni, Jayme Heim
Deucravacitinib improves Dermatology Life Quality Index in moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials
Matthias Augustin, Bruce Strober, April W. Armstrong, Jennifer Beaumont, Tan P. Pham, Stacie Hudgens, Joe Zhuo, Brandon Becker, Subhashis Banerjee, Renata M. Kisa, Kim A. Papp
Deucravacitinib significantly improves symptoms and signs of psoriasis in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials
April W. Armstrong, Bruce Strober, Joe Zhuo, Brandon Becker, Subhashis Banerjee, Andrew Napoli, Renata M. Kisa, John Throup, Kim A. Papp
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis
Leon Kircik, Matthew Zirwas, Shawn G. Kwatra, G. Michael Lewitt, Holly Glover, Tomas Chao, Philip M. Brown, David S. Rubenstein, Anna M. Tallman
Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial
Bruce Strober, Joshua A. Zeichner, Seemal R. Desai, Michael Cameron, Jennifer Cather, Matthew J. Bruno, David S. Rubenstein, Anna M. Tallman, Philip M. Brown